Lilly shares on track for worst day since 2021 after downbeat Zepbound sales forecast
Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...
Addressing the controversial 'O': All you need to know about Ozempic and why it’s trending
Ozempic, approved for Type 2 diabetes, has gained fame for its weight-loss properties, especially among celebrities. Despite its rising popularity, experts warn of potential side effects like ...